Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Raised to $36.00 at JPMorgan Chase & Co.

Day One Biopharmaceuticals (NASDAQ:DAWN - Free Report) had its price objective upped by JPMorgan Chase & Co. from $32.00 to $36.00 in a research note published on Monday, Benzinga reports. They currently have an overweight rating on the stock.

A number of other research analysts have also weighed in on DAWN. Oppenheimer reissued a market perform rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating for the company in a research report on Tuesday, February 27th. Finally, Piper Sandler reissued an overweight rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $39.83.

Day One Biopharmaceuticals Price Performance

Shares of DAWN stock traded up $0.42 on Monday, hitting $15.38. The company's stock had a trading volume of 663,485 shares, compared to its average volume of 645,529. Day One Biopharmaceuticals has a fifty-two week low of $9.67 and a fifty-two week high of $17.85. The firm's fifty day moving average price is $15.22 and its 200-day moving average price is $13.73. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.45 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). Analysts predict that Day One Biopharmaceuticals will post -2.66 EPS for the current fiscal year.

Insider Activity

In other news, CEO Jeremy Bender sold 7,615 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $116,128.75. Following the completion of the transaction, the chief executive officer now owns 721,813 shares of the company's stock, valued at $11,007,648.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Jeremy Bender sold 7,615 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $116,128.75. Following the sale, the chief executive officer now owns 721,813 shares of the company's stock, valued at $11,007,648.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Samuel C. Blackman sold 10,000 shares of the company's stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $16.01, for a total transaction of $160,100.00. Following the completion of the sale, the insider now directly owns 1,184,662 shares in the company, valued at approximately $18,966,438.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,781 shares of company stock valued at $722,960. Insiders own 8.40% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DAWN. SG Americas Securities LLC grew its stake in Day One Biopharmaceuticals by 58.7% during the third quarter. SG Americas Securities LLC now owns 36,980 shares of the company's stock worth $454,000 after buying an additional 13,683 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Day One Biopharmaceuticals by 22.4% during the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company's stock worth $2,703,000 after purchasing an additional 40,387 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Day One Biopharmaceuticals by 24.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company's stock worth $535,000 after purchasing an additional 8,522 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Day One Biopharmaceuticals by 100.0% during the third quarter. TD Asset Management Inc now owns 55,196 shares of the company's stock worth $677,000 after purchasing an additional 27,598 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of Day One Biopharmaceuticals by 89.5% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company's stock worth $660,000 after purchasing an additional 25,414 shares in the last quarter. Institutional investors own 87.95% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.